Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Journal of Medicinal Chemistry · 28.09.2023 · 66 (18) · 13280-13303
DOI: 10.1021/acs.jmedchem.3c01264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.09.2023. Verfasst von Weiguo Xiang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Androgen, Antineoplastic Agents. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, Proteovant Therapeutics Inc.
Abstract (Originalsprache)
We report herein the discovery and extensive characterization of ARD-1676, a highly potent and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was designed using a new class of AR ligands and a novel cereblon ligand. It has DC50 values of 0.1 and 1.1 nM in AR+ VCaP and LNCaP cell lines, respectively, and IC50 values of 11.5 and 2.8 nM in VCaP and LNCaP cell lines, respectively. ARD-1676 effectively induces degradation of a broad panel of clinically relevant AR mutants. ARD-1676 has an oral bioavailability of 67, 44, 31, and 99% in mice, rats, dogs, and monkeys, respectively. Oral administration of ARD-1676 effectively reduces the level of AR protein in the VCaP tumor tissue in mice and inhibits tumor growth in the VCaP mouse xenograft tumor model without any sign of toxicity. ARD-1676 is a highly promising development candidate for the treatment of AR+ human prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Oncopia Therapeutics Inc, 2 West Liberty Blvd., Malvern, Pennsylvania 19355, United States.
ORCID-Profile: Tianfeng Xu, Chong Qin, Chao-Yie Yang, Duxin Sun, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- Proteovant Therapeutics Inc
- Oncopia Therapeutics Inc
Zitieren
APA
Xiang, W., Zhao, L., Han, X., Xu, T., Kregel, S., Wang, M., Miao, B., Qin, C., Wang, M., McEachern, D., Lu, J., Bai, L., Yang, C. Y., Kirchhoff, P. D., Takyi-Williams, J., Wang, L., Wen, B., Sun, D., Ator, M., …, & Wang, S. (2023). Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. Journal of Medicinal Chemistry, 66(18), 13280-13303. https://doi.org/10.1021/acs.jmedchem.3c01264
Vancouver
Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, et al. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. Journal of Medicinal Chemistry. 2023;66(18):13280-13303. doi:10.1021/acs.jmedchem.3c01264
BibTeX
@article{Xiang2023,
author = {Xiang, Weiguo and Zhao, Lijie and Han, Xin and Xu, Tianfeng and Kregel, Steven and Wang, Mi and Miao, Bukeyan and Qin, Chong and Wang, Mingliang and McEachern, Donna and Lu, Jianfeng and Bai, Longchuan and Yang, Chao-Yie and Kirchhoff, Paul D and Takyi-Williams, John and Wang, Lu and Wen, Bo and Sun, Duxin and Ator, Mark and Mckean, Robert and Chinnaiyan, Arul M and Wang, Shaomeng},
title = {Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {18},
pages = {13280--13303},
doi = {10.1021/acs.jmedchem.3c01264}
}
EUVIMED